guest ::
| Home > Publications database > EASIX and mortality after allogeneic stem cell transplantation. > print |
| Home > Publications database > EASIX and mortality after allogeneic stem cell transplantation. > print |
| 001 | 147216 | ||
| 005 | 20240229123021.0 | ||
| 024 | 7 | _ | |a 10.1038/s41409-019-0703-1 |2 doi |
| 024 | 7 | _ | |a pmid:31558788 |2 pmid |
| 024 | 7 | _ | |a 0268-3369 |2 ISSN |
| 024 | 7 | _ | |a 0951-3078 |2 ISSN |
| 024 | 7 | _ | |a 1476-5365 |2 ISSN |
| 024 | 7 | _ | |a altmetric:67524091 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2019-02342 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Luft, Thomas |b 0 |
| 245 | _ | _ | |a EASIX and mortality after allogeneic stem cell transplantation. |
| 260 | _ | _ | |a London |c 2020 |b Nature Publishing Group55086 |
| 264 | _ | 1 | |3 online |2 Crossref |b Springer Science and Business Media LLC |c 2019-09-26 |
| 264 | _ | 1 | |3 print |2 Crossref |b Springer Science and Business Media LLC |c 2020-03-01 |
| 264 | _ | 1 | |3 print |2 Crossref |b Springer Science and Business Media LLC |c 2020-03-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1586872335_14355 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2020 Mar;55(3):553-561 |
| 520 | _ | _ | |a Allogeneic stem cell transplantation (alloSCT) is an effective immunotherapy in patients with hematological malignancies. Endothelial dysfunction was linked to major complications after alloSCT. We asked the question if the 'Endothelial Activation and Stress Index' (EASIX; [(creatinine × LDH) ÷ thrombocytes]) can predict mortality after alloSCT. We performed a retrospective cohort analysis in five alloSCT centers in the USA and Germany. EASIX was assessed prior to conditioning (EASIX-pre) and correlated with mortality in 755 patients of a training cohort in multivariable models. The predictive model established in the training cohort was validated in 1267 adult allo-recipients. Increasing EASIX-pre predicted lower overall survival (OS) after alloSCT, and successful model validation was achieved for the validation cohort. We found that EASIX-pre predicts OS irrespective of established scores. Moreover, EASIX-pre was also a significant prognostic factor for transplant-associated microangiopathy. Finally, EASIX-pre correlated with biomarkers of endothelial homeostasis such as CXCL8, interleukin-18, and insulin-like-growth-factor-1 serum levels. This study establishes EASIX-pre based on a standard laboratory biomarker panel as a predictor of individual risk of mortality after alloSCT independently from established clinical criteria. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 542 | _ | _ | |i 2019-09-26 |2 Crossref |u http://www.springer.com/tdm |
| 542 | _ | _ | |i 2019-09-26 |2 Crossref |u http://www.springer.com/tdm |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 1 |u dkfz |
| 700 | 1 | _ | |a Terzer, Tobias |0 P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e |b 2 |u dkfz |
| 700 | 1 | _ | |a Jodele, Sonata |b 3 |
| 700 | 1 | _ | |a Dandoy, Christopher E |0 0000-0002-4001-9203 |b 4 |
| 700 | 1 | _ | |a Storb, Rainer |0 0000-0002-9343-4099 |b 5 |
| 700 | 1 | _ | |a Kordelas, Lambros |0 0000-0003-3116-473X |b 6 |
| 700 | 1 | _ | |a Beelen, Dietrich |b 7 |
| 700 | 1 | _ | |a Gooley, Ted |b 8 |
| 700 | 1 | _ | |a Sandmaier, Brenda M |b 9 |
| 700 | 1 | _ | |a Sorror, Mohamed |b 10 |
| 700 | 1 | _ | |a Zeisbrich, Markus |b 11 |
| 700 | 1 | _ | |a Radujkovic, Aleksandar |b 12 |
| 700 | 1 | _ | |a Dreger, Peter |b 13 |
| 700 | 1 | _ | |a Penack, Olaf |b 14 |
| 773 | 1 | 8 | |a 10.1038/s41409-019-0703-1 |b Springer Science and Business Media LLC |d 2019-09-26 |n 3 |p 553-561 |3 journal-article |2 Crossref |t Bone Marrow Transplantation |v 55 |y 2019 |x 0268-3369 |
| 773 | _ | _ | |a 10.1038/s41409-019-0703-1 |0 PERI:(DE-600)2004030-1 |n 3 |p 553-561 |t Bone marrow transplantation |v 55 |y 2019 |x 0268-3369 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:147216 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BONE MARROW TRANSPL : 2014 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.1200/JCO.2006.09.7865 |9 -- missing cx lookup -- |1 ML Sorror |p 4246 - |2 Crossref |u Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25:4246–54. |t J Clin Oncol |v 25 |y 2007 |
| 999 | C | 5 | |a 10.1016/S0140-6736(98)03030-X |9 -- missing cx lookup -- |1 A Gratwohl |p 1087 - |2 Crossref |u Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087–92. |t Lancet |v 352 |y 1998 |
| 999 | C | 5 | |a 10.1002/cncr.24531 |9 -- missing cx lookup -- |1 A Gratwohl |p 4715 - |2 Crossref |u Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115:4715–26. |t Cancer |v 115 |y 2009 |
| 999 | C | 5 | |a 10.1182/blood-2012-03-418202 |9 -- missing cx lookup -- |1 P Armand |p 905 - |2 Crossref |u Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120:905–13. |t Blood |v 120 |y 2012 |
| 999 | C | 5 | |a 10.1038/bmt.2016.141 |9 -- missing cx lookup -- |1 M Elsawy |p 1283 - |2 Crossref |u Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51:1283–1300. |t Bone Marrow Transplant |v 51 |y 2016 |
| 999 | C | 5 | |a 10.1016/j.bbmt.2005.06.001 |9 -- missing cx lookup -- |1 VT Ho |p 571 - |2 Crossref |u Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2005;11:571–5. |t Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant |v 11 |y 2005 |
| 999 | C | 5 | |a 10.1182/blood-2016-08-736314 |9 -- missing cx lookup -- |1 K Riesner |p 2021 - |2 Crossref |u Riesner K, Shi Y, Jacobi A, Krater M, Kalupa M, McGearey A, et al. Initiation of acute graft-versus-host disease by angiogenesis. Blood. 2017;129:2021–32. |t Blood |v 129 |y 2017 |
| 999 | C | 5 | |a 10.3324/haematol.10699 |9 -- missing cx lookup -- |1 T Ruutu |p 95 - |2 Crossref |u Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92:95–100. |t Haematologica |v 92 |y 2007 |
| 999 | C | 5 | |a 10.1182/bloodadvances.2018020321 |9 -- missing cx lookup -- |1 SA Wall |p 2619 - |2 Crossref |u Wall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, et al. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Adv. 2018;2:2619–28. |t Blood Adv |v 2 |y 2018 |
| 999 | C | 5 | |a 10.1038/bmt.2017.119 |9 -- missing cx lookup -- |1 M Zeisbrich |p 1399 - |2 Crossref |u Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, et al. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone marrow Transplant. 2017;52:1399–405. |t Bone marrow Transplant |v 52 |y 2017 |
| 999 | C | 5 | |a 10.1182/blood-2018-02-791509 |9 -- missing cx lookup -- |1 S Paczesny |p 2193 - |2 Crossref |u Paczesny S. Biomarkers for posttransplantation outcomes. Blood. 2018;131:2193–204. |t Blood |v 131 |y 2018 |
| 999 | C | 5 | |a 10.1056/NEJMc1700185 |9 -- missing cx lookup -- |1 SJ Rotz |p 1189 - |2 Crossref |u Rotz SJ, Dandoy CE, Davies SM. ST2 and endothelial injury as a link between GVHD and microangiopathy. N Engl J Med. 2017;376:1189–90. |t N Engl J Med |v 376 |y 2017 |
| 999 | C | 5 | |a 10.1056/NEJMoa1213299 |9 -- missing cx lookup -- |1 MT Vander Lugt |p 529 - |2 Crossref |u Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369:529–39. |t N Engl J Med |v 369 |y 2013 |
| 999 | C | 5 | |a 10.1182/blood-2015-08-663435 |9 -- missing cx lookup -- |1 S Jodele |p 989 - |2 Crossref |u Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2016;127:989–96. |t Blood |v 127 |y 2016 |
| 999 | C | 5 | |a 10.1182/blood-2011-02-334821 |9 -- missing cx lookup -- |1 T Luft |p 1685 - |2 Crossref |u Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood. 2011;118:1685–92. |t Blood |v 118 |y 2011 |
| 999 | C | 5 | |a 10.1200/JCO.2013.54.4056 |9 -- missing cx lookup -- |1 SP Rachakonda |p 3421 - |2 Crossref |u Rachakonda SP, Penack O, Dietrich S, Blau O, Blau IW, Radujkovic A, et al. Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease. J Clin Oncol. 2014;32:3421–7. |t J Clin Oncol |v 32 |y 2014 |
| 999 | C | 5 | |a 10.1200/JCO.2017.76.4662 |9 -- missing cx lookup -- |1 SP Rachakonda |p 789 - |2 Crossref |u Rachakonda SP, Dai H, Penack O, Blau O, Blau IW, Radujkovic A, et al. Single nucleotide polymorphisms in CD40L predict endothelial complications and mortality after allogeneic stem-cell transplantation. J Clin Oncol. 2018;36:789–800. |t J Clin Oncol |v 36 |y 2018 |
| 999 | C | 5 | |a 10.1016/S2352-3026(17)30108-4 |9 -- missing cx lookup -- |1 T Luft |p e414 - |2 Crossref |u Luft T, Benner A, Jodele S, Dandoy CE, Storb R, Gooley T, et al. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol. 2017;4:e414. |t Lancet Haematol |v 4 |y 2017 |
| 999 | C | 5 | |a 10.1002/bimj.200610301 |9 -- missing cx lookup -- |1 TA Gerds |p 1029 - |2 Crossref |u Gerds TA, Schumacher M. Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biometrical J. 2006;48:1029–40. |t Biometrical J |v 48 |y 2006 |
| 999 | C | 5 | |a 10.3324/haematol.2013.090209 |9 -- missing cx lookup -- |1 S Dietrich |p 541 - |2 Crossref |u Dietrich S, Okun JG, Schmidt K, Falk CS, Wagner AH, Karamustafa S, et al. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy. Haematologica. 2014;99:541–7. |t Haematologica |v 99 |y 2014 |
| 999 | C | 5 | |a 10.1155/2014/549315 |9 -- missing cx lookup -- |1 W Hanf |p 549315 - |2 Crossref |u Hanf W, Bonder CS, Coates PT. Transplant glomerulopathy: the interaction of HLA antibodies and endothelium. J Immunol Res. 2014;2014:549315. |t J Immunol Res |v 2014 |y 2014 |
| 999 | C | 5 | |1 J Chopra |y 1987 |2 Crossref |u Chopra J, Joist JH, Webster RO. Loss of 51chromium, lactate dehydrogenase, and 111indium as indicators of endothelial cell injury. Lab Invest. 1987;57:578–84. |
| 999 | C | 5 | |a 10.1371/journal.pone.0010208 |9 -- missing cx lookup -- |1 P Coppo |p e10208 - |2 Crossref |u Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE. 2010;5:e10208. |t PLoS ONE |v 5 |y 2010 |
| 999 | C | 5 | |a 10.1007/s00277-015-2452-6 |9 -- missing cx lookup -- |1 F Ayuk |p 1727 - |2 Crossref |u Ayuk F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, et al. Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. Ann Hematol. 2015;94:1727–32. |t Ann Hematol |v 94 |y 2015 |
| 999 | C | 5 | |a 10.1378/chest.14-1246 |9 -- missing cx lookup -- |1 Y Wei |p 607 - |2 Crossref |u Wei Y, Wang Z, Su L, Chen F, Tejera P, Bajwa EK, et al. Platelet count mediates the contribution of a genetic variant in LRRC16A to ARDS risk. Chest. 2015;147:607–17. |t Chest |v 147 |y 2015 |
| 999 | C | 5 | |a 10.1038/bmt.2017.119 |9 -- missing cx lookup -- |1 M Zeisbrich |p 1399 - |2 Crossref |u Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, et al. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant. 2017;52:1399–1405. |t Bone Marrow Transplantation |v 52 |y 2017 |
| 999 | C | 5 | |a 10.5858/arpa.2013-0182-RA |9 -- missing cx lookup -- |1 TC Allen |p 266 - |2 Crossref |u Allen TC, Kurdowska A. Interleukin 8 and acute lung injury. Arch Pathol Lab Med. 2014;138:266–9. |t Arch Pathol Lab Med |v 138 |y 2014 |
| 999 | C | 5 | |a 10.1016/j.brainres.2013.05.047 |9 -- missing cx lookup -- |1 C Pieper |p 1 - |2 Crossref |u Pieper C, Pieloch P, Galla HJ. Pericytes support neutrophil transmigration via interleukin-8 across a porcine co-culture model of the blood-brain barrier. Brain Res. 2013;1524:1–11. |t Brain Res |v 1524 |y 2013 |
| 999 | C | 5 | |a 10.1096/fasebj.13.15.2195 |9 -- missing cx lookup -- |1 R Cao |p 2195 - |2 Crossref |u Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J. 1999;13:2195–202. |t FASEB J |v 13 |y 1999 |
| 999 | C | 5 | |a 10.1126/scitranslmed.3007616 |9 -- missing cx lookup -- |1 SL Doyle |p 230ra44 - |2 Crossref |u Doyle SL, Ozaki E, Brennan K, Humphries MM, Mulfaul K, Keaney J, et al. IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration. Sci Transl Med. 2014;6:230ra44. |t Sci Transl Med |v 6 |y 2014 |
| 999 | C | 5 | |a 10.1093/cvr/cvv107 |9 -- missing cx lookup -- |1 MC Durpes |p 303 - |2 Crossref |u Durpes MC, Morin C, Paquin-Veillet J, Beland R, Pare M, Guimond MO, et al. PKC-beta activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis. Cardiovasc Res. 2015;106:303–13. |t Cardiovasc Res |v 106 |y 2015 |
| 999 | C | 5 | |a 10.1016/j.jvs.2007.12.005 |9 -- missing cx lookup -- |1 JM Li |p 1048 - |2 Crossref |u Li JM, Eslami MH, Rohrer MJ, Dargon P, Joris I, Hendricks G, et al. Interleukin 18 binding protein (IL18-BP) inhibits neointimal hyperplasia after balloon injury in an atherosclerotic rabbit model. J Vasc Surg. 2008;47:1048–57. |t J Vasc Surg |v 47 |y 2008 |
| 999 | C | 5 | |a 10.1530/JME-14-0215 |9 -- missing cx lookup -- |1 LA Bach |p R1 - |2 Crossref |u Bach LA. Endothelial cells and the IGF system. J Mol Endocrinol. 2015;54:R1–13. |t J Mol Endocrinol |v 54 |y 2015 |
| 999 | C | 5 | |a 10.1038/bmt.2017.43 |9 -- missing cx lookup -- |1 S Weischendorff |p 863 - |2 Crossref |u Weischendorff S, Kielsen K, Sengelov H, Jordan K, Nielsen CH, Pedersen AE, et al. Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:863–9. |t Bone Marrow Transplant |v 52 |y 2017 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|